D011810Chemicals & DrugsD03.633.100.8577110.989672QuinoxalinesFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson0.9767880.007053957research area of0.7704750.028510310subject area for31096006Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MWJournal of hepatologyPatient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019 09; 71(3):486-497.J Hepatol2019-05-13T00:00:002019Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.31534310Cotter TG, Jensen DMDrug design, development and therapyGlecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther. 2019; 13:2565-2577.Drug Des Devel Ther2019-07-29T00:00:002019Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.DavidWilliamsDavid Lee Williams349574Williams, DavidAssociate ProfessorNancyReauNancy Reau349580Reau, NancyProfessorJohnSegretiJohn Segreti349648Segreti, JohnProfessorGordonTrenholmeGordon M. Trenholme349698Trenholme, GordonProfessor5Associate Professor4Professor32459122Asselah T, Zeuzem S, Reau N, Hwang P, Long J, Talwani R, Robertson MN, Haber BACurrent medical research and opinionEfficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin. 2020 08; 36(8):1325-1332.Curr Med Res Opin2020-06-24T00:00:002020Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis.23891152Nguyen JB, Pool CD, Wong CY, Treger RS, Williams DL, Cappello M, Lea WA, Simeonov A, Vermeire JJ, Modis YChemistry & biologyPeroxiredoxin-1 from the human hookworm Ancylostoma ceylanicum forms a stable oxidized decamer and is covalently inhibited by conoidin A. Chem Biol. 2013 Aug 22; 20(8):991-1001.Chem Biol2013-07-25T00:00:002013Peroxiredoxin-1 from the human hookworm Ancylostoma ceylanicum forms a stable oxidized decamer and is covalently inhibited by conoidin A.Rush University, Rush Medical Collegetrue1ProfessorProfessorInternal Medicine, Division of Digestive Diseases and NutritionDonaldJensenDonald M. Jensen349747Jensen, DonaldProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessorInternal Medicine, Division of Infectious Diseasestrue1Associate ProfessorAssociate ProfessorMicrobial Pathogens and Immunity29672891Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns XHepatology (Baltimore, Md.)Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 10; 68(4):1298-1307.Hepatology2018-07-25T00:00:002018Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.